Omeros (OMER) Given a $24.00 Price Target at Maxim Group

Maxim Group set a $24.00 price target on Omeros (NASDAQ:OMER) in a research note issued to investors on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on OMER. HC Wainwright set a $30.00 target price on shares of Omeros and gave the stock a buy rating in a research report on Thursday, December 14th. Zacks Investment Research upgraded shares of Omeros from a hold rating to a strong-buy rating and set a $22.00 target price for the company in a research report on Thursday, October 19th. Wedbush reiterated an outperform rating and issued a $47.00 target price on shares of Omeros in a research report on Tuesday, November 28th. Finally, Cowen lowered shares of Omeros from an outperform rating to a market perform rating in a research report on Thursday, November 2nd. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $34.14.

Shares of Omeros (OMER) traded down $0.06 during trading hours on Wednesday, reaching $19.70. 863,400 shares of the company traded hands, compared to its average volume of 1,342,967. Omeros has a one year low of $8.71 and a one year high of $27.09. The stock has a market capitalization of $938.01, a price-to-earnings ratio of -15.27 and a beta of 3.56. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million during the quarter, compared to analysts’ expectations of $17.82 million. During the same quarter last year, the firm posted ($0.34) earnings per share. The firm’s revenue was up 91.9% on a year-over-year basis. equities analysts predict that Omeros will post -0.98 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. AMP Capital Investors Ltd bought a new stake in Omeros in the third quarter worth $279,000. Stifel Financial Corp raised its stake in shares of Omeros by 10.7% during the third quarter. Stifel Financial Corp now owns 394,428 shares of the biopharmaceutical company’s stock valued at $8,522,000 after acquiring an additional 38,268 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Omeros by 10.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 217,804 shares of the biopharmaceutical company’s stock valued at $4,709,000 after acquiring an additional 20,139 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Omeros by 13.8% during the third quarter. Wells Fargo & Company MN now owns 42,144 shares of the biopharmaceutical company’s stock valued at $911,000 after acquiring an additional 5,102 shares during the last quarter. Finally, First Interstate Bank bought a new position in shares of Omeros during the third quarter valued at about $108,000. 49.71% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Omeros (OMER) Given a $24.00 Price Target at Maxim Group” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3127237/omeros-omer-given-a-24-00-price-target-at-maxim-group.html.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.